Sign in
William Dubin

William Dubin

Research Analyst at Leerink

New York, NY, US

William Dubin is an Equity Research Analyst at Leerink Partners, specializing in healthcare and life sciences investment research. He covers companies such as KalVista Pharmaceuticals and has participated in public earnings calls to provide analytical insights, contributing to sector-focused investment strategies. Dubin began his career at Fidelity Investments before gaining experience at North River Company and BLDUP, and later joined Leerink Partners following roles at Moelis & Company. He maintains professional credentials through FINRA registration and securities licenses, demonstrating compliance and expertise in regulated financial activities.

William Dubin's questions to KalVista Pharmaceuticals (KALV) leadership

Question · Q1 2026

William Dubin sought more detail on the patient profile beyond prior therapy, specifically asking about any meaningful patterns observed in attack rate severity, attack frequency, and typical attack rates before initiating ECTERLEET treatment.

Answer

Nicole Sweeny, Chief Commercial Officer, indicated that while market research suggested early adopters would be high-burden patients, adoption has been seen across a wide array of patient types and burden of disease. She noted that the utilization of prophylaxis among ECTERLEET patients aligns with overall market share for prophylaxis, demonstrating broad population use regardless of disease burden or prior/current treatment.

Ask follow-up questions

Fintool

Fintool can predict KalVista Pharmaceuticals logo KALV's earnings beat/miss a week before the call

Question · Q1 2026

William Dubin sought more information on the patient profile beyond prior therapy, specifically asking about meaningful patterns in attack rate severity, attack frequency, and typical attack rates before initiating EKTERLY treatment.

Answer

Nicole Sweeny, Chief Commercial Officer, stated that while market research indicated high-burden patients would be early adopters, adoption has been observed across a wide array of patient types and burden of disease. She added that current prophylaxis utilization among EKTERLY patients aligns with overall market share, indicating broad use regardless of prior on-demand or current prophylactic treatment.

Ask follow-up questions

Fintool

Fintool can write a report on KalVista Pharmaceuticals logo KALV's next earnings in your company's style and formatting